pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

7,888 catalysts · 4,728 grant · 4,244 device 510k · 3,606 8k filing · 3,160 approval · 2,000 device pma · 2,000 device recall

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-31: 3 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 1 catalyst2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 18 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts2026-11-09: 1 catalyst2026-11-10: 0 catalysts2026-11-11: 0 catalysts2026-11-12: 0 catalysts2026-11-13: 0 catalysts2026-11-14: 0 catalysts2026-11-15: 0 catalysts2026-11-16: 0 catalysts2026-11-17: 0 catalysts2026-11-18: 0 catalysts2026-11-19: 0 catalysts2026-11-20: 0 catalysts2026-11-21: 0 catalysts2026-11-22: 0 catalysts2026-11-23: 0 catalysts2026-11-24: 0 catalysts2026-11-25: 0 catalysts2026-11-26: 0 catalysts2026-11-27: 0 catalysts2026-11-28: 0 catalysts2026-11-29: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
type: approval×type: grant×from 2024-12-18×clear all
type
  • grant4,728
  • device 510k4,244
  • 8k filing3,606
  • approval3,160
  • device pma2,000
  • device recall2,000
recall
1,027
  • device adverse event1,000
  • earnings585
  • phase 2 completion172
  • therapy area

    no tagged catalysts yet

    Week of Dec 16, 2024

    27
    ›Dec 18, 2024approval622d agoENSACOVE (ENSARTINIB HYDROCHLORIDE) — FDA approvalensartinib hydrochloride

    Sponsor: XCOVERY. Form: CAPSULE. Route: ORAL

    full page →ensartinib hydrochloride →fda approvals ↗
    ›Dec 18, 2024approval622d agoIDACIO (ADALIMUMAB-AACF) — FDA approvalIDACIO

    Sponsor: FRESENIUS KABI USA. Form: INJECTABLE. Route: SUBCUTANEOUS

    full page →IDACIO →fda approvals ↗
    ›Dec 18, 2024approval622d agoRETEVMO (SELPERCATINIB) — FDA approvalselpercatinib

    Sponsor: ELI LILLY AND CO. Form: CAPSULE. Route: ORAL

    full page →selpercatinib →fda approvals ↗
    ›Dec 18, 2024approval622d agoRETEVMO (SELPERCATINIB) — FDA approvalselpercatinib

    Sponsor: ELI LILLY AND CO. Form: CAPSULE. Route: ORAL

    full page →selpercatinib →fda approvals ↗
    ›Dec 19, 2024approval621d agoGABAPENTIN — FDA approvalGABAPENTIN

    Sponsor: STRIDES PHARMA. Form: CAPSULE. Route: ORAL

    full page →GABAPENTIN →fda approvals ↗
    ›Dec 19, 2024approval621d agoGABAPENTIN — FDA approvalGABAPENTIN

    Sponsor: STRIDES PHARMA. Form: CAPSULE. Route: ORAL

    full page →GABAPENTIN →fda approvals ↗
    ›Dec 19, 2024approval621d agoGABAPENTIN — FDA approvalGABAPENTIN

    Sponsor: STRIDES PHARMA. Form: CAPSULE. Route: ORAL

    full page →GABAPENTIN →fda approvals ↗
    ›Dec 19, 2024approval621d agoGABAPENTIN — FDA approvalAlmatica Pharma LLC

    Sponsor: ALKEM. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Dec 19, 2024approval621d agoCEREZYME (IMIGLUCERASE) — FDA approvalimiglucerase

    Sponsor: GENZYME. Form: INJECTABLE. Route: INJECTION

    full page →imiglucerase →fda approvals ↗
    ›Dec 19, 2024approval621d agoGABAPENTIN — FDA approvalGABAPENTIN

    Sponsor: SANDOZ. Form: CAPSULE. Route: ORAL

    full page →GABAPENTIN →fda approvals ↗
    ›Dec 19, 2024approval621d agoVEKLURY (REMDESIVIR) — FDA approvalremdesivir

    Sponsor: GILEAD SCIENCES INC. Form: SOLUTION. Route: INTRAVENOUS

    full page →remdesivir →fda approvals ↗
    ›Dec 20, 2024approval620d agoSKYCLARYS (OMAVELOXOLONE) — FDA approvalReata Pharmaceuticals Inc

    Sponsor: BIOGEN US. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Dec 20, 2024approval620d agoSKYCLARYS (OMAVELOXOLONE) — FDA approvalReata Pharmaceuticals Inc

    Sponsor: BIOGEN US. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Dec 20, 2024approval620d agoALYFTREK (DEUTIVACAFTOR) — FDA approval(deutivacaftor + tezacaftor + vanzacaftor calcium)

    Sponsor: VERTEX PHARMS INC. Form: TABLET. Route: ORAL

    full page →(deutivacaftor + tezacaftor + vanzacaftor calcium) →fda approvals ↗
    ›Dec 20, 2024approval620d agoTRIKAFTA (COPACKAGED) (ELEXACAFTOR, IVACAFTOR, TEZACAFTOR) — FDA approvalTRIKAFTA (COPACKAGED)

    Sponsor: VERTEX PHARMS INC. Form: TABLET. Route: ORAL

    full page →TRIKAFTA (COPACKAGED) →fda approvals ↗
    ›Dec 20, 2024approval620d agoTRIKAFTA (COPACKAGED) (ELEXACAFTOR, IVACAFTOR, TEZACAFTOR) — FDA approvalTRIKAFTA (COPACKAGED)

    Sponsor: VERTEX PHARMS INC. Form: TABLET. Route: ORAL

    full page →TRIKAFTA (COPACKAGED) →fda approvals ↗
    ›Dec 20, 2024approval620d agoTRIKAFTA (COPACKAGED) (ELEXACAFTOR, IVACAFTOR, TEZACAFTOR) — FDA approvalTRIKAFTA (COPACKAGED)

    Sponsor: VERTEX PHARMS INC. Form: GRANULES. Route: ORAL

    full page →TRIKAFTA (COPACKAGED) →fda approvals ↗
    ›Dec 20, 2024approval620d agoTRIKAFTA (COPACKAGED) (ELEXACAFTOR, IVACAFTOR, TEZACAFTOR) — FDA approvalTRIKAFTA (COPACKAGED)

    Sponsor: VERTEX PHARMS INC. Form: GRANULES. Route: ORAL

    full page →TRIKAFTA (COPACKAGED) →fda approvals ↗
    ›Dec 20, 2024approval620d agoIMCIVREE (SETMELANOTIDE ACETATE) — FDA approvalsetmelanotide

    Sponsor: RHYTHM. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →setmelanotide →fda approvals ↗
    ›Dec 20, 2024approval620d agoZEPBOUND (TIRZEPATIDE) — FDA approvalZEPBOUND

    Sponsor: ELI LILLY AND CO. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →ZEPBOUND →fda approvals ↗
    ›Dec 20, 2024approval620d agoBRAFTOVI (ENCORAFENIB) — FDA approvalencorafenib

    Sponsor: ARRAY BIOPHARMA INC. Form: CAPSULE. Route: ORAL

    full page →encorafenib →fda approvals ↗
    ›Dec 20, 2024approval620d agoPYZCHIVA (USTEKINUMAB-TTWE) — FDA approvalPYZCHIVA

    Sponsor: SAMSUNG BIOEPIS CO LTD. Form: INJECTABLE. Route: INJECTION

    full page →PYZCHIVA →fda approvals ↗
    ›Dec 20, 2024approval620d agoPYZCHIVA (USTEKINUMAB-TTWE) — FDA approvalPYZCHIVA

    Sponsor: SAMSUNG BIOEPIS CO LTD. Form: INJECTABLE. Route: SUBCUTANEOUS

    full page →PYZCHIVA →fda approvals ↗
    ›Dec 20, 2024approval620d agoPYZCHIVA (USTEKINUMAB-TTWE) — FDA approvalPYZCHIVA

    Sponsor: SAMSUNG BIOEPIS CO LTD. Form: INJECTABLE. Route: SUBCUTANEOUS

    full page →PYZCHIVA →fda approvals ↗
    ›Dec 20, 2024approval620d agoIMBRUVICA (IBRUTINIB) — FDA approvalAbbVie Inc.

    Sponsor: PHARMACYCLICS LLC. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Dec 20, 2024approval620d agoIMBRUVICA (IBRUTINIB) — FDA approvalAbbVie Inc.

    Sponsor: PHARMACYCLICS LLC. Form: SUSPENSION. Route: ORAL

    full page →fda approvals ↗
    ›Dec 20, 2024approval620d agoIMBRUVICA (IBRUTINIB) — FDA approvalAbbVie Inc.

    Sponsor: PHARMACYCLICS LLC. Form: TABLET. Route: ORAL

    full page →fda approvals ↗

    Week of Dec 23, 2024

    5
    ›Dec 23, 2024approval617d agoYUFLYMA (ADALIMUMAB-AATY) — FDA approvalYUFLYMA

    Sponsor: CELLTRION. Form: INJECTABLE. Route: INJECTION

    full page →YUFLYMA →fda approvals ↗
    ›Dec 26, 2024approval

    Week of Dec 30, 2024

    11
    ›Dec 30, 2024approval610d agoREZUROCK (BELUMOSUDIL MESYLATE) — FDA approvalbelumosudil mesylate

    Sponsor: KADMON PHARMS LLC. Form: TABLET. Route: ORAL

    full page →belumosudil mesylate →fda approvals ↗
    ›Dec 31, 2024approval

    Week of Jan 6, 2025

    7
    ›Jan 7, 2025approval602d agoGABAPENTIN — FDA approvalGABAPENTIN

    Sponsor: ACTAVIS ELIZABETH. Form: CAPSULE. Route: ORAL

    full page →GABAPENTIN →fda approvals ↗
    ›Jan 7, 2025approval
    ← prev
    page 1 of 158
    next →
    614d ago
    EBANGA (ANSUVIMAB-ZYKL) — FDA approvalansuvimab

    Sponsor: RIDGEBACK BIOTHERAPEUTICS. Form: POWDER. Route: IV (INFUSION)

    full page →ansuvimab →fda approvals ↗
    ›Dec 26, 2024approval614d agoWEZLANA (USTEKINUMAB-AUUB) — FDA approvalWEZLANA

    Sponsor: AMGEN INC. Form: INJECTABLE. Route: INTRAVENOUS, SUBCUTANEOUS

    full page →WEZLANA →fda approvals ↗
    ›Dec 26, 2024approval614d agoWEZLANA (USTEKINUMAB-AUUB) — FDA approvalWEZLANA

    Sponsor: AMGEN INC. Form: INJECTABLE. Route: INTRAVENOUS, SUBCUTANEOUS

    full page →WEZLANA →fda approvals ↗
    ›Dec 27, 2024approval613d agoOPDIVO QVANTIG (NIVOLUMAB) — FDA approval(hyaluronidase (recombinant, human) + nivolumab)

    Sponsor: BRISTOL-MYERS SQUIBB. Form: INJECTABLE. Route: SUBCUTANEOUS

    full page →(hyaluronidase (recombinant, human) + nivolumab) →fda approvals ↗
    609d ago
    SPRAVATO (ESKETAMINE HYDROCHLORIDE) — FDA approvalJanssen Therapeutics

    Sponsor: JANSSEN PHARMS. Form: SPRAY. Route: NASAL

    full page →fda approvals ↗
    ›Dec 31, 2024approval609d agoGABAPENTIN — FDA approvalSciegen Pharmaceuticals Inc

    Sponsor: SCIEGEN PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Dec 31, 2024approval609d agoGABAPENTIN — FDA approvalSciegen Pharmaceuticals Inc

    Sponsor: SCIEGEN PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Dec 31, 2024approval609d agoGABAPENTIN — FDA approvalSciegen Pharmaceuticals Inc

    Sponsor: SCIEGEN PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Dec 31, 2024approval609d agoRELGAABI (GABAPENTIN) — FDA approvalSciegen Pharmaceuticals Inc

    Sponsor: SCIEGEN PHARMS. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Dec 31, 2024approval609d agoRELGAABI (GABAPENTIN) — FDA approvalSciegen Pharmaceuticals Inc

    Sponsor: SCIEGEN PHARMS. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Dec 31, 2024approval609d agoRELGAABI (GABAPENTIN) — FDA approvalSciegen Pharmaceuticals Inc

    Sponsor: SCIEGEN PHARMS. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Dec 31, 2024approval609d agoGABAPENTIN — FDA approvalAlmatica Pharma LLC

    Sponsor: LAURUS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Dec 31, 2024approval609d agoGABAPENTIN — FDA approvalAlmatica Pharma LLC

    Sponsor: LAURUS. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Jan 3, 2025approval606d agoPYRUKYND (MITAPIVAT SULFATE) — FDA approvalAGIOS PHARMACEUTICALS, INC.

    Sponsor: AGIOS PHARMS INC. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    602d ago
    GABAPENTIN — FDA approvalGABAPENTIN

    Sponsor: ACTAVIS ELIZABETH. Form: CAPSULE. Route: ORAL

    full page →GABAPENTIN →fda approvals ↗
    ›Jan 7, 2025approval602d agoDEMEROL (MEPERIDINE HYDROCHLORIDE) — FDA approvalMEPERIDINE HYDROCHLORIDE

    Sponsor: HOSPIRA. Form: INJECTABLE. Route: INJECTION

    full page →MEPERIDINE HYDROCHLORIDE →fda approvals ↗
    ›Jan 8, 2025approval601d agoLAMOTRIGINE — FDA approvalZydus Therapeutics Inc

    Sponsor: ZYDUS PHARMS. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →fda approvals ↗
    ›Jan 10, 2025approval599d agoFLONASE SENSIMIST ALLERGY RELIEF (FLUTICASONE FUROATE) — FDA approvalGlaxoSmithKline LLC

    Sponsor: HALEON US HOLDINGS. Form: SPRAY, METERED. Route: NASAL

    full page →fda approvals ↗
    ›Jan 10, 2025approval599d agoFLONASE ALLERGY RELIEF (FLUTICASONE PROPIONATE) — FDA approvalParatek Pharmaceuticals Inc

    Sponsor: HALEON US HOLDINGS. Form: SPRAY, METERED. Route: NASAL

    full page →fda approvals ↗
    ›Jan 10, 2025approval599d agoVEKLURY (REMDESIVIR) — FDA approvalremdesivir

    Sponsor: GILEAD SCIENCES INC. Form: SOLUTION. Route: INTRAVENOUS

    full page →remdesivir →fda approvals ↗
    $VERX14.22-0.52%
    $LLY1174.61-0.13%
    $VERX14.22-0.52%
    $GILD145.68-2.14%
    $RYTM107.17-4.76%
    $LLY1174.61-0.13%
    $VERX14.22-0.52%
    $LLY1174.61-0.13%
    $VERX14.22-0.52%
    $VERX14.22-0.52%
    $ABBV255.48-1.03%
    $AVBP30.17-2.68%
    $AMGN432.42-1.05%
    $ABBV255.48-1.03%
    $AMGN432.42-1.05%
    $BMY66.58-0.55%
    $ABBV255.48-1.03%
    $AGIO33.32-2.80%
    $GILD145.68-2.14%